The Ministry of Health of Kazakhstan has submitted for discussion a draft order regulating the list of medicines and medical products for free and preferential outpatient provision, a Kazinform agency correspondent reports.
Discussion project will last until May 20, 2026.
As noted in the explanation, updating the list is aimed at expanding patient access to modern and effective drugs, as well as bringing the drug supply system in line with current clinical recommendations and international practice.
The project includes 23 innovative medicines for 16 nosologies. In particular, for children with chronic heart failure, it is proposed to add the drugs “Ivabradine” and the combination “Sacubitril/Valsartan”. For patients with severe forms of bronchial asthma, the inclusion of Omalizumab is provided.
In addition, the list of therapies for patients with juvenile arthritis is expanding – it is proposed to include Canakinumab, Tocilizumab, Golimumab and Adalimumab.
At the same time, the document provides for the exclusion of a number of outdated medicinal items that have lost their relevance taking into account modern standards of treatment. According to the department, this will improve the efficiency of outpatient drug provision and ensure a more rational use of budget funds.
The project was developed based on the decisions of the Formulary Commission and is aimed at improving the quality of medical care. It is expected that if the changes are adopted, patients will be able to receive treatment in accordance with modern standards.
Earlier in the Ministry of Health denied the reports about the sharp rise in drug prices.
